ERRATA CORRIGE



Interleukin-1 receptor associated kinase 1/4 and
bromodomain and extra-terminal inhibitions converge
on NF-kB blockade and display synergistic antitumoral
activity in activated B-cell subset of diffuse large B-cell
lymphoma with MYD88 L265P mutation
Ivan Dlouhy,1,2* Marc Armengol,3* Clara Recasens-Zorzo,2 Marcelo L Ribeiro,3,4 Patricia Pérez-       Correspondence: G. Roué
Galán,2 Francesc Bosch,5 Armando López-Guillermo1,2# and Gaël Roué3#                                 groue@carrerasresearch.org

                                                                                                     Received:        August 22, 2022.
.                                                                                                    Accepted:        August 22, 2022.

                                                                                                     https://doi.org/10.3324/haematol.2022.281988

                                                                                                     ©2022 Ferrata Storti Foundation
                                                                                                     Published under a CC BY-NC license




Erratum to ms. HAEMATOL/2020/278258. “Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal
inhibitions converge on NF-kB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse
large B-cell lymphoma with MYD88 L265P mutation” Haematologica. 2021 Oct 1;106(10):2749-2753. doi: 10.3324/haema-
tol.2020.278258. PMID: 33979991; PMCID: PMC8485659.

Gaël Roué, as corresponding author of the above-referenced article, declares that the request for an addition of a new af-
filiation for one of the authors (M. Armengol) has been approved by all co-authors. This modification is a prerequisite of
Barcelona Autonomous University’s Doctorate program to enable the inclusion of this work in the doctoral thesis of M. Ar-
mengol.



The author and affiliation information should be indicated as follows:

Ivan Dlouhy,1,2* Marc Armengol,3,4* Clara Recasens-Zorzo,2 Marcelo L Ribeiro,3,5 Patricia Pérez-Galán,2 Francesc Bosch,6
Armando López-Guillermo1,2# and Gaël Roué3#


1
 Department of Hematology, Hospital Clínic, BarceIona, Spain; 2Division of Hematology and Oncology, Institut d’Investigacions Biomèdiques
August Pi i Sunyer (IDIBAPS), CIBERONC, Barcelona, Spain; 3Lymphoma Translational Group, Josep Carreras Leukaemia Research Institute
(IJC), Badalona, Spain; 4Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona, Barcelona, Spain 5Post
Graduate Program in Health Science, Universidade São Francisco (USF), Bragança Paulista, Brazil and 6Laboratory of Experimental
Hematology, Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Universitat
Autònoma de Barcelona, Barcelona, Spain.




                                                       Haematologica | 107 December 2022
                                                                     2990